A novel candidate disease genes prioritization method based on module partition and rank fusion

OMICS A Journal of Integrative Biology

Volumn 14, Issue 4, 2010, Pages 337-356

  Chen, Xing ^a,b   Yan, Gui Ying ^a   Liao, Xiao Ping ^a,b  

^a CHINESE ACADEMY OF SCIENCES   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; FUSION GENE; GENE LOCATION; HUMAN GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GENE;

ALGORITHMS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DISEASE; FEMALE; GENE REGULATORY NETWORKS; GENES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77956047866     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2009.0143     Document Type: Article

References (98)

1. Adie, E.A., Adams, R.R., Evans, K.L., Porteous, D.J., and Pickard, B.S. (2005). Speeding disease gene discovery by sequence based candidate prioritization. BMC Bioinformatics 6, 55.
2. Adie, E.A., Adams, R.R., Evans, K.L., Porteous, D.J., and Pickard, B.S. (2006). SUSPECTS: enabling fast and effective prioritization of positional candidates. Bioinformatics 22, 773-774.
3. Aerts, S., Lambrechts, D., Maity, S., Van Loo, P., Coessens, B., Smet, F.F., et al. (2006). Gene prioritization through genomic data fusion. Nat Biotechnol 24, 537-544.
4. Agarwal, R. (2000). Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60, 1051-1059.
5. Ala, U., Piro, R.M., Grassi, E., Damasco, C., Silengo, L., Oti, M., et al. (2008). Prediction of human disease genes by human-mouse conserved co-expression analysis. PLoS Comput Biol 3, e1000043.
6. Angele, S., Falconer, A., Edwards, S.M., Dork, T., Bremer, M., Moullan, N., et al. (2004). ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 91, 783-787.
7. Arason, A., Barkardottir, R.B., and Egilsson V. (1993). Linkage analysis of chromosome 17q markers and breast-ovarian cancer in icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 52, 711-717.
8. Barabá si, A., and Oltvai, Z.N. (2004). Network biology: understanding the cell's functional organization. Nat Rev Genet 5, 101-113.
9. Berns, E.M., de Klein, A., van Putten, W.L., van Staveren, I.L., Bootsma. A., Klijn, J.G., et al. (1995). Association between rb-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int J Cancer 2, 140-145.
10. Botstein, D., and Risch, N. (2003). Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex diseases. Nat Genet 33, 228-237.
11. Botstein, D., White, R.L., Skolnick, R., and Davis, R.D. (1980). Constructing of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 32, 314-331.
12. Bouras, T., Southey, M.C., and Venter, D.J. (2001). Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 3, 930-937.
13. Brunner, H.G., and van Driel, M.A. (2004). From syndrome families to functional genomics. Nat Rev Genet 5, 545-551.
14. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T.C., et al. (1999). Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59, 803-806.
15. Buschmann, T., Minamoto, T., Wagle, N., Fuchs, S.Y., Adler, V., Mai, M., et al. (2000). Analysis of JNK, Mdm2 and p14ARF contribution to the regulation of mutant p53 stability. J Mol Biol 295, 1009-1021.
16. Chang, B.L., Zheng, S.L., Isaacs, S.D., Wiley, K.E., Turner, A., Li, G., et al. (2004). A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 64, 1997-1999.
17. Chen, X.F., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee C., et al. (2001). Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 42, 6073-6083.
18. Chen, J., Aronow, B.J., and Jegga, A.G. (2009). Disease candidate gene identification and prioritization using protein interaction networks. BMC bioinformatics 10, 73.
19. Chien, J., Narita, K., Rattan, R., Giri, S., Shridhar, R., Staub, J., et al. (2008). A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclinD1 levels and cellular transformation. Oncogene 27, 7223-7234.
20. Chin, K., Solorzano, C.S.D., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., et al. (2004). In situ analyses of genome instability in breast cancer. Nat Genet 36, 984-988.
21. Cox, D.G, Hankinson, S.E., and Hunter, D.J. (2006). Polymorphisms of the AURKA (STK15/aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control 17, 81-83.
22. Damaraju, S., Murray, D., Dufour, J., Carandang, D., Myrehaug, S., Fallone, G., et al. (2006). Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 15, 2545-2554.
23. DeMarzo, A.M., Nelson, W.G., Isaccs, W.B., and Epstein, J.I. (2003). Pathological and molecular aspects of prostate cancer. Lancet 9361, 955-996.
24. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P.P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27, 222-224.
25. Ding, S.L., Yu, J.C., Chen, S.T., Hsu, G.C., Kuo, Y.H., Lin, Y.H., et al. (2009). Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis 30, 43-49.
26. Ditemann, S., Georgii, E., Antonov, A., Tsuda, K., and Mewes, H. (2009). The DICS repository:module-assisted analysis of diseaserelated gene lists. Bioinformatics 6, 830-831.
27. Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., Iruela-Arispe, M.L., Zhang, J.F., Matusik, R., et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 3, 223-238.
28. Enright, A.J., Van-Dongen, S., and Ouzounis, C.A. (2002). An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res 30, 1575-1584.
29. Fortunato, S., and Castellano, C. (2007). Community structure in graphs. Eprint arXiv:0712.2716.
30. Franke, L., van Bakel, H., Fokkens, L., De Jong, E.D., Egmont-Petersen, M., and Wijmenga, C. (2006). Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes. Am J Hum Genet 78, 1011-1025.
31. Gandhi, T.K., Zhong J., Mathivanan, S., Karthick, L., Chandrika, K.N., Mohan, S.S., et al. (2006). Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 38, 285-293.
32. Gao, S., Zacharek, A., Salkowski, A., Grignon, D.J., Sakr, W., Porter, A.T., et al. (1995). Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cance. Cancer Res 55, 1002-1005.
33. Gao, X., Grignon, D.J., Chbihi, T., Zacharek, A., Chen, Y.Q., Sakr, W., et al. (1995). Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46, 227-237.
34. Glazier, A.M., Nadeau, J.H., and Aitman, T.J. (2002). Finding genes that underlie complex traits. Science 298, 2345-2349.
35. Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A., and McKusick, V.A. (2005). Online mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33, 514-517.
36. Hao, F., Tan, M.Q., Xu, X.M., Han, J.H., Miller, D.D., Tigyi, G., et al. (2007). Lysophosphatidic acid induces prostate cancer pc3 cell migration via activation of lpa(1), p42 and p38alpha. Biochim Biophys Acta 1771, 883-892.
37. Ho, G.Y.F., Melman, A., Liu, S.M., Li, M., Yu, H., Negassa A., et al. (2003). Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer 88, 263-269.
38. Hutz, J.Z., Kraja, A.T., Mcleod, H.L., and Province, M.A. (2008). CANDID: A flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol.
39. Isaacs, W., and Kainu, T. (2001). Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 32, 779-790.
40. Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., and Hattori, M. (2004). The KEGG resource for deciphering the genome. Nucleic Acids Res 23, 277-280.
41. Kann, M.G. (2010). Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform 11, 96-110.
42. Karppinena, S.M., Erkkoa, H., Reinib, K., Pospiechc, H., Heikkinena, K., Rapakkoa, K., et al. (2006). Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer. Eur J Cancer 15, 2647-2652.
43. Kibel, A.S., Suarez, B.K, Belani, J., Oh, J., Webster, R., Brophy-Ebbers, M., et al. (2003). CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 63, 2033-2036.
44. Köhler, S., Bauer, S., Horn, D., and Robinson, P.N. (2008). Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82, 949-958.
45. Kokontis, J., Takakura, K., Hay, N., and Liao, S. (1994). Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54, 1566-1573.
46. Kubota, Y., Fujinami, K., Uemura, H., Dobashi, Y., Miyamoto, H., Iwasaki, Y., et al. (1995). Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27, 314-320.
47. Lage, K., Karlberg, E.O., Storling, Z.M., Olason, P.I., Pedersen, A.G., Rigina, O., et al. (2007). A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 25, 309-316.
48. Lancichinetti, A., and Fortunato, S. (2009). Community detection algorithms: a comparative analysis. Phys Rev E 80, 056117.
49. Langston, A.A., Stanford, J., Wicklund, K.G., Thompson, J.D., Blazej, R.G., and Ostrander, E.A. (1996). Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 58, 881-885.
50. Latil, A., Bièche, I., Pesche, S., Volant, A., Valèri, A., Fournier, G., et al. (1999). Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. Hum Pathol 7, 809-815.
51. Li, C.D., Larsson, C., Futreal, A., Lancaster, J., Phelan, C., Aspenblad, U., et al. (1998). Identification of twodistinct deleted regions on chromosome 13 in prostate cancer. Oncogene 4, 481-487.
52. Li, LC., Zhao, H., Shiina, H., Kane, C.J., and Dahiya, R. (2003). Pgdb: a curated and integrated database of genes related to the prostate. Nucleic Acids Res 31, 291-293.
53. Li, LC., Okino, S.T., and Dahiya, R. (2004). DNA methylation in prostate cancer. Bionchim Biophys Acta 6, 87-102.
54. Lim, J., Hao, T., Shaw, C., Patel. A.J., Szabo, G., Rual, J.F., et al. (2006). A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125, 801-814.
55. Linda, B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., et al. (2002). Constitutive activation of Stat3 in human prostate tumors and cell lines. Cancer Res 62, 6659-6666.
56. Majumder, P.K., Sellers, W.R. (2005). Akt-regulated pathways in prostate cancer. Oncogene 24, 7465-7474.
57. Matsuyama, M., Yoshimura, R., Mitsuhashi, M., Hase, T., Tsuchida, K., Takemoto, Y., et al. (2004). Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitor. Int J Oncol 24, 821-827.
58. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
59. Morrison, J.L., Breitling, R., Higham, D.J., and Gilbert, D.R. (2005). GeneRank: using search engine technology for the analysis of microarray experiments. BMC Bioinformatics 6, 233.
60. Muhlbauer, K.R., Grone, H.J., Ernst, T., Grone, E., Tschada, R., Hergenhahn, M., et al. (2003). Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer 89, 687-690.
61. Nesterov, A., Lu, X.J., Johnson, M., Milleri, G.J., Ivashchenko, Y., and Kraft A.S. (2001). Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 14, 10767-10774.
62. Olapade-Olaopa, E.O., Moscatello, D.K., MacKay, E.H., Horsburgh, T., Sandhu, D.P.S, Terry T.R., et al. (2000). Evidence for differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82, 186-194.
63. Osman, I., Drobnjak, M., Fazzari, M., Ferrara, J., Scher, H.I., and Cordon-Cardo, C. (1999). Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5, 2082-2088.
64. Oti, M., and Brunner, H.G. (2007). The modular nature of genetic diseases. Clin Genet 71, 1-11.
65. Oti, M., Reeuwijk, V.J., Huynen, M.A., and Brunner, H.G. (2008). Conserved co-expression for candidate disease gene prioritization. BMC Bioinformatics 9, 208-210.
66. Ozgur, A., Vu, T., Erkan, G., and Radev, D.R. (2008). Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 24, 277-285.
67. Palla, G., Derenyi, I., Farkas, I., and Vicsek, T. (2005). Uncovering the overlapping community structure of complex networks in nature and society. Nature 9, 814-818.
68. Palmer, D.H., Hussain, S.A., Ganesan, R., Cooke, P.W., Wallace, D.M., Young, L.S., et al. (2004). CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep 4, 679-682.
69. Ponzielli, R., Katz, S., Barsyte-Lovejoy, D., and Penn, L.Z. (2005). Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41, 2485-2501.
70. Pujana, M.A., Han, J.D.J., Starita, L.M., Stevens, K.N., Tewari, M., Ahn J.S., et al. (2007). Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat.Genet 11, 1338-1349.
71. Rosvall, M., and Bergstrom, C.T. (2008). Maps of random walks on complex networks reveal community structure. Proc Natl Acad Sci 105, 1118-1123.
72. Sabatini, D.M. (2006). mTOR and cancer: insights into a complex relationship. Net Rev Cancer 6, 729-734.
73. Sarfaraz, S., Afaq, F., Adhami, V.M., Malik, A., and Mukhtaret, H. (2006). Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells lncap proceeds through sustained activation of erk1/2 leading to g1 cell cycle arrest. J Biol Chem 281, 39480-39491.
74. Sharpless, N.E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. J Mutat Res 576, 22-38.
75. Stark, C., Breitkreutz, B.J., Reguly, T., Boucher, L., Breitkreutz, A., and Tyerset, M. (2006). BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34, 535-539.
76. Stenson, P.D., Ball, W.V., Mort, M., Phillips, A.D., Shiel, J.A., Thomas, N.S.T., et al. (2003). Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21, 577-581.
77. Stubbs, A.P., Abel, P.D., Golding, M., Bhangal, G., Wang, Q., Waxman, J., et al. (1999). Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with geneticaberrations Am J Pathol 5, 1335-1343.
78. Tiffin, N., Kelso, J.F., Powell, A.R., Pan, H., Bajic, V.B., and Hide, W.A. (2005). Integration of text-and data-mining using ontologies successfully selects disease gene candidates. Nucleic Acids Res 33, 1544-1552.
79. Tranchevent, L., Barriot, R., Yu, S., Van Vooren, S., Van Loo, P., Coessens, B., et al. (2008). ENDEAVOUR update: a web resource for gene prioritization in multiple species. Nucleic Acids Res 36, 377-384.
80. Tsuruoka, Y., Tateishi, Y., Kim, J.D., Ohta, T., Mcnaught, J., et al. (2005). Developing a robust part-of-speech tagger for biomedical text. In Proceedings of the 10th Panhellenic Conference on Informatics, Volos, Greece, LNCS 3746, pp. 382-392.
81. Van Dongen, S. (2000). Graph clustering by flow simulation. PHD Thesis, University of Utrecht, The Netherlands.
82. Van Driel, M.A.V., Bruggeman, J., Vriend, G., Brunner, H.G., and Leunissen, J.A.M. (2006). A text-mining analysis of the human phenome. Eur J Hum Genet 14, 535-542.
83. Vanunu, O., Magger, O., Ruppin, E., Shlomi, P., and Sharan, R. (2010). Associating genes and protein complexes with disease via network propagation. PLoS Comput Biol 6, e1000641.
84. Vara, J.A.F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and Gonzalez-Baron, M. (2004). PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 30, 193-204.
85. Wain, H.M., Lush, M.J., Ducluzeau, F., Khodiyar, V.K., and Povey, S. (2004). Genew: the human gene nomenclature database, 2004 updates. Nucleic Acids Res 32, 1257-1261.
86. Wang, H., Yu, D., Agrawal, S., and Zhang, R.W. (2003). Experimental therapy of human prostate cancer by inhibiting mdm2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54, 194-205.
87. Wang, L., Sun, F.Z., and Chen, T. (2008). Prioritizing functional modules mediating genetic perturbations and their phenotypic effects: a global strategy. Genome Biol 12, 537-544.
88. Wang, L.Z., Habuchi, T., Mitsumori, K., Li, Z.H., Kamoto, T., Kinoshita, H., et al. (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103, 116-120.
89. Wei, Q., Li, M., Fu, X., Tang, R., Na, Y., Jiang, M., et al. (2007). Global analysis of differentially expressed genes in androgenindependent prostate cancer. Prostate Cancer Prostatic Dis 10, 167-174.
90. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
91. Wu, G.J., Sinclair, C.S., Paape, J., Ingle, J.N., Roche, P.C., James, C.D., et al. (2000). 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGMA1B genes. Cancer Res 60, 5371-5375.
92. Wu, X.B., Jiang, R., Zhang, M.Q., and Li, S. (2008). Networkbased global inference of human disease genes. Mol Syst Biol 4, 189-199.
93. Wu, X.B., Liu, Q.F., and Jiang, R. (2009). Align human interactome with phenome to identify causative genes and networks underlying disease families. Bioinformatics 25, 98-104.
94. Xu, W.S., Ngo, L., Perez, G., Dokmanovic, M., and Marks, P.A. (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 42,15540-15545.
95. Yee, C.J., Roodi, N., Verrier, C.S., and Parl, F.F. (1994). Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res 7, 1641-1644.
96. Zhang, Z., Li, M., Wang, H., Agrawal, S., and Zhang, R.W. (2003). Antisense therapy targeting mdm2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100, 11636-11641.
97. Zhao, C., Yasui, K., Lee, C.J., Kurioka, H., Hosokawa, Y., Oka, T., et al. (2003). Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 1, 18-23.
98. Zi, X.L., and Agarwal. R. (1999). Silibinin decreases prostatespecific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 13, 7490-7495.